Skip to main content
SpringerLink
Log in

Pharmakokinetik und therapeutisches Monitoring von Antidepressiva

  • Conference paper
Depression 2000

  • 214 Accesses

Zusammenfassung

Die Behandlung der Depression hat in den vergangenen Jahren erhebliche Fortschritte verzeichnet durch die Weiterentwicklung von verschiedenen psychotherapeutischen Therapieformen, durch die Erkenntnis, dass eine Kombination von psychotherapeutischen mit psychopharmakologischen Therapien die besten Voraussetzungen für einen Therapieerfolg bietet, aber auch durch die Einführung von neuen, besser verträglichen Medikamenten, wie z. B. den Serotoninwieder-aufnahmehemmern (SSRI). Die zunehmende „Medikalisierung“ der Psychiatrie hat zur Einführung von operationalisierten Vorgehensweisen bei der Diagnose der Krankheit und ihrer Behandlung geführt. Zu dieser Strategie zählt auch die Anwendung von Plasmaspiegelbestimmungen (Therapeutisches Drug Monitoring, TDM) von Antidepressiva zur Therapieüberwachung (Balant-Gorgia u. Balant 1995; Hiemke et al. 2000 a; Hiemke et al. 2000 b; Baumann 1990; Ulrich et al. 2000; Burke u. Preskorn 1999). Die Einführung pharmakogenetischer Tests zur Charakterisierung des Metabolisierungspotenzials beim einzelnen Patienten ist hierbei eine wertvolle Ergänzung des TDMs (Baumann et al. 2000).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Akiskal HS (1985) A proposed clinical approach to chronic and „resistant“ depressions: evaluation and treatment. J Clin Psychiatry 46:32–36.

    PubMed  CAS  Google Scholar 

  • Arranz MJ, Munro J, Birkett J et al. (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615–1616.

    Article  PubMed  CAS  Google Scholar 

  • Asberg M, Crönholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 3:331–334.

    Article  PubMed  CAS  Google Scholar 

  • Balant-Gorgia EA, Balant LP (1995) Therapeutic drug monitoring - Relevance during the drug treatment of psychiatric disorders. CNS Drugs 4:432–453.

    Article  CAS  Google Scholar 

  • Baumann P (1990) Pharmakokinetische Aspekte der Therapieresistenz mit Antidepressiva. In: Möller H-J (Hrsg) Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin, Heidelberg New York Tokyo, S 85–98.

    Google Scholar 

  • Baumann P (1998) Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 13 [Suppl 5]:S35–S43.

    Article  PubMed  Google Scholar 

  • Baumann P, Broly F, Kosel M, Eap CB (1998) Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry 31:72.

    Article  PubMed  CAS  Google Scholar 

  • Baumann P, Eap CB, de Mendonça Lima CA, Zullino D (1998) Characteristics of psychotropic drug metabolism in geriatric patients. In: Brunello N, Langer SZ, Racagni G (eds) Mental disorders in the elderly: new therapeutic approaches. International Academy for Biomedical and Drug Research, Basel, pp 159–170.

    Chapter  Google Scholar 

  • Baumann P, Eap CB, Steimer W, Kosel M, Voirol P (1999) Ultraschnelle Metabolisierer. Grundlagen und klinische Bedeutung. Psychopharmakotherapie 6:62–64.

    Google Scholar 

  • Baumann P, Kosel M, Voirol P (2000) Pharmakogenetische Charakterisierung - Pharmakogenetik in der Psychopharmakologie. In: Gastpar M, Banger M (Hrsg) Laboruntersuchungen in der psychiatrischen Routine. Thieme, Stuttgart New York, S 134–149.

    Google Scholar 

  • Baumann P, Nil R, Souche A et al. (1996) A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16:307–314.

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson L, Dahl M-L, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 96 [Suppl 391]:14–21.

    Article  Google Scholar 

  • Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, Baettig D, Baumann P (1992) Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Int J Clin Pharmacol Ther 52:350–358.

    Article  CAS  Google Scholar 

  • Burke MJ, Preskorn SH (1999) Therapeutic drug monitoring of antidepressants - Cost implications and relevance to clinical practice. Clin Pharmacokinet 37:147–165.

    Article  PubMed  CAS  Google Scholar 

  • Chou WH, Yan F-X, Barnhill J et al. (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246–251.

    Article  PubMed  CAS  Google Scholar 

  • Ciraulo DA, Shader RI, Greenblatt DJ, Barnhill JG (1995) Basic concepts. In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL (eds) Drug Interactions in Psychiatry. Williams & Wilkins, Maryland, USA, pp 1–28.

    Google Scholar 

  • Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P (1996) Pharmacokinetic fluvoxamine - clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 29: 108–110.

    Article  PubMed  CAS  Google Scholar 

  • Dahl M-L, Sjöqvist F (2000) Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 22:114–117.

    Article  PubMed  CAS  Google Scholar 

  • DeVane CL, Sallee FR (1996) Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 57:55–66.

    PubMed  CAS  Google Scholar 

  • DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment - Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107.

    Article  PubMed  CAS  Google Scholar 

  • Donoghue J, Taylor DM (2000) Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 13:365–383.

    Article  CAS  Google Scholar 

  • Eap CB, Bertel-Laubscher R, Zullino D, Amey M, Baumann P (2000) Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 33:112–115.

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754.

    Article  PubMed  CAS  Google Scholar 

  • Fava M (2000) New approaches to the treatment of refractory depression. J Clin Psychiatry 61 [Suppl 1]:26–32.

    PubMed  Google Scholar 

  • Fredman SJ, Rosenbaum JF (1998) Recurrent depression, resistant clinician? Harv Rev Psychiatry 5:281–285.

    Article  PubMed  CAS  Google Scholar 

  • George C, Peveler RC, Heiliger S, Thompson C (2000) Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol 50:166–171.

    Article  PubMed  CAS  Google Scholar 

  • Gervot L, Rochat B, Gautier JC et al. (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306.

    Article  PubMed  CAS  Google Scholar 

  • Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C (1998) Serum concentrations of fluvoxamine and clinical effects. Pharmacopsychiatry 31:199–200.

    Article  PubMed  Google Scholar 

  • Heyn H, White RB, Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948–954.

    PubMed  CAS  Google Scholar 

  • Hiemke C, Härtter S, Weigmann H (2000) Therapeutisches Drug Monitoring (TDM). In: Gastpar M, Banger M (Hrsg) Laboruntersuchungen in der psychiatrischen Routine. Thieme, Stuttgart New York, S 106–133.

    Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Mann K (2000) Therapeutisches Drug Monitoring von Psychopharmaka. NeuroTransmitter 11:52–55.

    Google Scholar 

  • Lawrenson RA, Tyrer F, Newson RB, Farmer RDT (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59:149–157.

    Article  PubMed  CAS  Google Scholar 

  • Lundmark J, Bengtsson F, Nordin C, Reis M, Wålinder J (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101:354–359.

    Article  PubMed  CAS  Google Scholar 

  • Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667–1671.

    Article  PubMed  CAS  Google Scholar 

  • Nelson JC (2000) Augmentation strategies in depression 2000. J Clin Psychiatry 61 [Suppl 2]:13–19.

    PubMed  Google Scholar 

  • Opler LA, Ramirez PM (1998) Use of the Positive and Negative Syndrome Scale (PANSS) in clinical practice. J Pract Psychiatry Behav Health 4:157–162.

    Google Scholar 

  • Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235.

    PubMed  CAS  Google Scholar 

  • Perry PJ, Zeilmann C, Arndt S (1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14:230–240.

    Article  PubMed  CAS  Google Scholar 

  • Preskorn S, Jerkovich GS (1990) Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 10:88–95.

    Article  PubMed  CAS  Google Scholar 

  • Preskorn SH, Fast GA (1992) Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 53:160–162.

    PubMed  CAS  Google Scholar 

  • Rasmussen BB, Brøsen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143–154.

    Article  PubMed  CAS  Google Scholar 

  • Reynolds CF, III, Perel JM, Frank E et al. (1999) Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 156:1177–1181.

    PubMed  Google Scholar 

  • Rochat B, Amey M, Gillet M, Meyer UA, Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1–10.

    Article  PubMed  CAS  Google Scholar 

  • Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P (1998) Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 56:15–23.

    Article  PubMed  CAS  Google Scholar 

  • Schmider J, Greenblatt DJ, Von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 44:495–498.

    Article  PubMed  CAS  Google Scholar 

  • Sindrup SH, Brøsen K, Hansen MGJ et al. (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11–17.

    Article  PubMed  CAS  Google Scholar 

  • Ten Eick AP, Nakamura H, Reed MD (1998) Drug-drug interactions in pediatric psychopharmacology. Pediatr Clin North Am 45:1233–1264.

    Article  PubMed  Google Scholar 

  • Thase ME, Rush AJ (1997) When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 [Suppl 13]:23–29.

    PubMed  Google Scholar 

  • Ulrich S, Schrödter I, Partscht G, Baumann P (2000) Therapeutisches Drug-Monitoring von psychotropen Pharmaka - Eine allgemeine Einfuhrung. Psychopharmakotherapie 7:2–14.

    Google Scholar 

Download references

Authors
  1. P. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Zullino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. B. Eap
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fachkrankenhaus für Psychiatrie, Psychotherapie und Neurologie, Bezirksklinikum Gabersee, Gabersee 7, 83512, Wasserburg am Inn, Germany

    G. Laux

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Baumann, P., Zullino, D., Eap, C.B. (2002). Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. In: Laux, G. (eds) Depression 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59394-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59394-9_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63963-0

  • Online ISBN: 978-3-642-59394-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation